Adding chemotherapy to radiation treatment not effective in treating vulvar cancer

(Medical Xpress)—The addition of chemotherapy to post-surgical radiation treatment is not effective in treating vulvar cancer, according to Magee-Womens Hospital of UPMC research presented this week in San Francisco at the 56th annual meeting of the American Society for Radiation Oncology (ASTRO).

Vulvar cancer is extremely rare, accounting for just 4 percent of gynecologic cancers and 0.6 percent of cancers women face in the U.S. each year. Led by Sushil Beriwal, M.D., associate professor with the department of at the University of Pittsburgh School of Medicine and at Magee, this study identified patients diagnosed with vulvar cancer between 1998 and 2011 who had undergone surgery to remove the cancer and required adjuvant because the disease had spread to their lymph nodes.

The study utilized the National Cancer Database, a nationwide oncology outcomes database, to identify 1,087 patients who underwent in addition to radiation therapy after their initial surgery to remove the cancer. The study took into account factors including age, race, insurance coverage, tumor size and spread of the disease.

"Our study found that overall, the addition of chemotherapy to adjuvant radiation therapy did not improve patient survival," said Dr. Beriwal. "While retrospective studies do impose some limits on our conclusion, we found that at the very least, use of concurrent chemotherapy should be carefully evaluated on an individual basis."

While the study didn't confirm a benefit of the addition of to treatment, Dr. Beriwal said it is important to share the findings because they move researchers one step closer to understanding how to most effectively treat vulvar cancer.

Citation: Adding chemotherapy to radiation treatment not effective in treating vulvar cancer (2014, September 19) retrieved 18 March 2024 from https://medicalxpress.com/news/2014-09-adding-chemotherapy-treatment-effective-vulvar.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer

 shares

Feedback to editors